CT-412 ALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First-Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Large B-Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy
Year: 2024
Type: conference-abstract
Authors: Jason Westin, John Burke, Ryan Lynch, Jeremy Abramson, Don Stevens, Matthew Matasar, Lindsey Fitzgerald, Alan Zausner Skarbnik, Chaitanya Iragavarapu, James Essell, Bradley Hunter, Akil Merchant, Indumathy Varadarajan, Anand Rotte, Edward Licitra, Locke Bryan, Rushang D. Patel, Rajesh Behl, Jeff Sharmann, Houston E. Holmes, Suzanne Fanning, Habte Yimer, Mitul Gandhi, Gary Simmons, Amy Feng, Lynn Navale, Srinivas Ghatta, John B. Le Gall, Alex F. Herrera
Institutions: The University of Texas MD Anderson Cancer Center, Rocky Mountain Cancer Centers, Fred Hutch Cancer Center, Massachusetts General Hospital, Norton Healthcare, Robert Wood Johnson University Hospital, Huntsman Cancer Institute, Novant Health, University of Kentucky, Oncology Hematology Care, Intermountain Healthcare, Cedars-Sinai Medical Center, University of Virginia Health System, University of Virginia, Augusta University, AdventHealth, Alta Bates Summit Medical Center, Alta Bates Summit Medical Center, Willamette Valley Cancer Institute and Research Center, Texas Oncology, Prisma Health, Virginia Cancer Specialists, Virginia Oncology Associates, Allogene Therapeutics (United States), City Of Hope National Medical Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4401875563